OS Therapies CEO Paul Romness and CBO Gerald Commisiong Discuss Recent OST-HER2 Phase 2b Data and Next Steps

from WTR Healthcare Happenings · host Joe Brunetto

CEO Paul Romness and CBO Gerald Commisiong of OS Therapies join us on our WTR Biotech Spotlight podcast to talk about the OST-HER2 Phase 2b data in recurrent, liver metastatic osteosarcoma and what it could mean for patients with this aggressive cancer. We discuss the plan to approach the FDA and their confidence in a potential accelerated filing. Listen to learn more about OS Therapies and its cancer immunotherapy.

Episode metadata supplied by the publisher feed · Published Feb 12, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

OS Therapies CEO Paul Romness and CBO Gerald Commisiong Discuss Recent OST-HER2 Phase 2b Data and Next Steps

0:00 25:42

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of WTR Healthcare Happenings?

This episode is 25 minutes long.

When was this WTR Healthcare Happenings episode published?

This episode was published on February 12, 2025.

Can I download this WTR Healthcare Happenings episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!